Abstract
A Drug Information Association Workshop on “Statistical Methodology in Non-Clinical and Toxicological Studies” was held at the end of March 1996. The purpose of this meeting was to discuss and to obtain a consensus on the appropriateness of current and new biostatistical methods relevant in this field of drug development. The following summary represents a consensus of the Working Group on Biostatistics in Mutagenicity Studies. The recommendations outline the relevant principles of design and analysis rather than provide detailed specification of statistical methodology, thus providing the possibility of making reasonable choices between alternative approaches.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
The views are those of the authors and not necessarily those of their employers.
Rights and permissions
About this article
Cite this article
Hauschke, D., Hayashi, M., Lin, K.K. et al. Recommendations for Biostatistics of Mutagenicity Studies. Ther Innov Regul Sci 31, 323–326 (1997). https://doi.org/10.1177/009286159703100202
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286159703100202